Global Health

River blindness is still spreading near South Sudan's Maridi Dam, child serosurveys show

Repeated Ov16 antibody surveys in 3-to-4-year-olds found 33% seropositivity near the dam against 1% a few kilometres away, with no drop over seven years of control.

Onchocerciasis, the parasitic infection known as river blindness, is still being transmitted to young children living near the Maridi Dam in South Sudan despite years of intensified elimination efforts, a new serosurvey study concludes [s1]. Published in PLoS Neglected Tropical Diseases on 11 November, the study tracked antibodies to the parasite in children aged three to four, too young to have been exposed before control began, and found that infection is continuing at a sharply higher rate close to the dam than a short distance away [s1].

The marker the researchers used is the Ov16 antibody, a sign that a child has been exposed to Onchocerca volvulus [s1]. Because the parasite is spread by blackflies that breed in fast-flowing water, the dam's spillway is a plausible transmission hotspot; in 2019, biting rates there reportedly reached 202 flies per person-hour [s1]. Slash-and-clear vector control at the dam began in December 2019, and biannual community-directed ivermectin treatment started in 2021 after a distribution round was interrupted in 2020 [s1].

A steep gradient from the dam

In surveys conducted in February and July 2026, the team examined 195 children aged three to four across four settlements, 87 aged three and 108 aged four, 93 boys and 102 girls [s1]. Overall Ov16 seroprevalence was 18.5% (36 of 195; 95% confidence interval 13.4-24.8) [s1]. But that average masked a steep geographic gradient. In the two Kazana villages nearest the dam, seroprevalence was 33.3% (35 of 105), against just 1.1% (1 of 90) in the two more distant settlements of Hai-Tarawa and Hai-Gabat (p < 0.001) [s1]. At the extremes, Kazana 2 reached 49.1% (26 of 53) while Hai-Tarawa recorded no positive children at all (0 of 41) [s1].

Age sharpened the picture further. Seroprevalence rose from 11.5% in three-year-olds (10 of 87) to 24.1% in four-year-olds (26 of 108), a statistically significant increase (p = 0.024) consistent with continuing, year-on-year exposure [s1]. Near the dam, the jump was from 18.8% at age three to 45.6% at age four [s1]. There was no meaningful difference between boys and girls [s1]. Notably, no child had visible onchocercal nodules, and none had previously taken ivermectin [s1].

No sign of decline over seven years

Comparing the same four villages across three survey rounds, the researchers found no downward trend in young-child seropositivity: 14.3% in 2019 (6 of 42), 20.0% in 2023 (14 of 70) and 18.5% in 2026 (36 of 195), with no statistically significant difference between any pair of years (test for heterogeneity p = 0.744) [s1]. A mixed-effects model adjusting for age and sex likewise found no significant change, with odds ratios close to one for both 2023 and 2026 relative to 2019 [s1]. Near the dam, if anything, the figures edged up across the rounds, from 25.0% to 37.1% to 33.3% [s1].

The authors point to a shortfall in treatment reach as part of the explanation: therapeutic ivermectin coverage was 70.3% in 2023, below the roughly 80% level generally considered necessary to drive onchocerciasis toward elimination [s1].

What the study can and cannot say

This is a focused serosurvey, not a full entomological and parasitological assessment, and the authors are clear about the gaps [s1]. The 2026 surveys did not include skin-snip microfilarial testing or blackfly infection data, so the study documents exposure in children rather than directly measuring parasite loads or current vector infectivity [s1]. The comparison also rests on relatively small numbers in the earlier rounds, which widens the uncertainty around year-to-year change [s1]. The paper does not invoke a specific numeric seroprevalence threshold for declaring transmission interrupted [s1].

Within those limits, the signal is consistent and hard to dismiss: children born well after control intensified are still being infected, and most of that infection is clustered within a few kilometres of the dam [s1]. The authors call for consistently high ivermectin coverage paired with entomologically monitored vector control, arguing that a focal hotspot like the Maridi spillway can keep transmission alive even where programme indicators look adequate on paper [s1].

This article is informational and is not medical advice.

Sources

  1. Persistent focal onchocerciasis transmission near the Maridi Dam, South Sudan, despite intensified elimination interventions: Repeated Ov16 serosurveys in young children, 2019-2026 — PLoS Neglected Tropical Diseases , November 11, 2026
Related coverage